➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKinsey
Merck
Harvard Business School
Express Scripts

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,925,212


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,925,212 protect, and when does it expire?

Patent 9,925,212 protects VELTASSA and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 9,925,212
Title:Potassium-binding agents for treating hypertension and hyperkalemia
Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Inventor(s): Klaerner; Gerrit (Hillsborough, CA), Berman; Lance (San Francisco, CA)
Assignee: Relypsa, Inc. (Redwood City, CA)
Application Number:15/287,179
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,925,212
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,925,212

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF HYPERKALEMIA ⤷  Try it Free
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF HYPERKALEMIA ⤷  Try it Free
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF HYPERKALEMIA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,925,212

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013329451 ⤷  Try it Free
Australia 2018260862 ⤷  Try it Free
Australia 2020294307 ⤷  Try it Free
Brazil 112015007749 ⤷  Try it Free
Canada 2886788 ⤷  Try it Free
China 104822383 ⤷  Try it Free
European Patent Office 2916851 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
Baxter
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.